Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains how to consider dosing patients receiving Stivarga (regorafenib) as a result of the ReDOS study

Tags: ASCO GI Conference CoverageColorectal

Published: 26 January 2018

Recent Videos: ASCO GI Conference Coverage

video

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

Dr. Beer, Professor of Medicine, Oregon Health Sciences University, describes the use of DNA repair markers when determining treatment of ...

video

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, regarding the results of the TAPUR study presented at ASCO ...

video

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, determines whether to automatically test for the BRAF mutation in ...

video

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, shares how the recent clinical studies concerning "sided-ness" affects the ...

video

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, provided perspective on the combination of regorafenib and checkpoint inhibitors ...

video

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, elaborates on the influence of cell free DNA when making ...

video

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, offers opinion regarding checkpoint inhibitors being used in ...

video

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, discusses quality of life analysis in the IMBRAVE ...

video

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

Crystal Denlinger, MD, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, regarding cell free DNA tests and how ...

video

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, comments on the use of fitness trackers to ...

Related Videos

video-image

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

video-image

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

video-image

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

video-image

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

video-image

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

video-image

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

video-image

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

video-image

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

video-image

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

video-image

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

video-image

David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020

video-image

David H Ilson, MD, on the JAVELIN 100 study and the need for quick responses and immunotherapy in GE

video-image

Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy

video-image

Zev Wainberg, MD, explains appropriate therapy following initial treatment for GI & GE tumors

video-image

Zev Wainberg, MD, shares the best way to combine checkpoint inhibitors in gastric and GE tumors

video-image

Zev Wainberg, MD, on the line of therapy for checkpoint inhibitors in gastric and GI cancers

video-image

Hani Babiker, MD, on tumor treatment field combinations in the management of GI malignancies

video-image

Hani Babiker, MD, defines tumor treatment fields as well as the mechanism of action

video-image

Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment

video-image

Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC

video-image

Ahmed Kaseb, MD, shares the role of checkpoint inhibitors when alone and combined with anti-CTLA4

video-image

Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA

video-image

Irvin Modlin, MD, describes whether NETest replaces or supplements imaging

video-image

Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive

video-image

Irvin Modlin, MD, explains the specificity and sensitivity of the NETest

video-image

Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results

video-image

Nevena Damjanov, MD, shares personal opinion of treatment of patient with a high expression of AFP

video-image

Eileen O'Reilly, MD, shares outcomes of the POLO study and its importance to physicians

video-image

Eileen O'Reilly, MD, describes how physicians should test for BRCA in pancreatic cancer patients

video-image

Sam Klempner, MD, describes the role of Cyramza in the treatment of GR junction cancers

video-image

Sam Klempner, MD, considers promising approaches to therapy in development for upper GI malignancies

video-image

Manish Shah, MD, discusses avelumab's effectiveness based on results from the JAVELIN 100 study

video-image

Manish Shah, MD, explains whether levatinib can be combined with I-O to treat and manage GI cancer

video-image

Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients

video-image

Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility

video-image

Daniel Catenacci, MD, on the role of margetuximab to improve treatment outcomes of GI cancers

video-image

Daniel Catenacci, MD, shares opinion on the role of checkpoint inhibitors for GI malignancies

video-image

Philip Philip, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Philip Philip, MD, shares opinion on treatment of a BRCA+ pancreatic cancer patient

video-image

Philip Philip, MD, explains how physicians should test for BRCA in pancreatic cancer patients

video-image

Philip Philip, MD, on the outcomes of the POLO study and its importance to physicians

video-image

Daneng Li, MD, regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for HCC

video-image

Daneng Li, MD, shares latest thoughts on checkpoint inhibitors being combines with TKIs

video-image

Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment

video-image

Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time

video-image

Ryan Corcoran, explains cell free DNA and ways to test for it

video-image

Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma

video-image

Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC

video-image

Richard Kim, MD, on the combination of cabozantinib and checkpoint inhibitors to improve HCC outcomes

video-image

Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment

video-image

Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies

video-image

Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC

video-image

Philip Philip, MD, provides thoughts on the role of PARP inhibitors in advanced pancreatic cancer

video-image

Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age

video-image

Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients

video-image

David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients

video-image

David H Ilson, MD, shares results of the ARTDECO study and it's importance to physicians

video-image

Zev Wainberg, MD, shares results of study regarding gastric and GE cancers presented at ASCO GI

video-image

Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA

video-image

Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard

video-image

Daneng Li, MD, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes

video-image

Richard Kim, MD determines whether checkpoint inhibitors combine with regorafenib for HCC treatment

video-image

Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study

video-image

Hani Babiker, MD, elaborates on tumor treatment fields applying to GI malignancies

video-image

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

video-image

Ahmed Kaseb, MD, on combining cabozantinib with checkpoint inhibitors for treatment of HCC

video-image

Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study

video-image

Nevena Damjanov, MD, on impressions of the study combining cabozantinib with checkpoint inhibitors in advanced HCC patients

video-image

Nevena Damjanov, MD, elaborates on the role of TKIs in managing 2nd line HCC patients

video-image

Nevena Damjanov, MD, explains the outcomes of combining atezolizumab with bevacizumab in 1st line HCC patients

video-image

Eileen O'Reilly, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Eileen O'Reilly, MD, provides evidence to inform treatment of pancreatic cancer patients

video-image

Manish Shah, MD, regarding the use of liquid biopsy to diagnose and treat GI cancers

video-image

Manish Shah, MD, on the role of Cyramza in the treatment of gastric and esophageal cancers

video-image

Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancer

video-image

Daniel Catenacci, MD, elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020

video-image

Tanios Bekaii-Saab, MD, FACP discusses how strategies for the treatment of colorectal cancer patients has changed at the Mayo Clinic as a result of COVID-19

video-image

Tanios Bekaii-Saab, MD, FACP, describes deintensification strategies in the management of advanced colorectal cancer patients brought to the forefront by COVID-19

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC

video-image

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer

video-image

Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment

video-image

Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC

video-image

Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer

video-image

Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC